IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS Fort Worth Division

OUTSOURCING FACILITIES ASSOCIATION, et al.,

Plaintiffs,

v.

Civil Action No. 4:24-cv-00953-P

UNITED STATES FOOD AND DRUG ADMINISTRATION, et al.,

Defendants.

Appendix (Vol II of IV) in Support of Plaintiffs' Motion for a <u>Preliminary Injunction and Stay Pending Review</u>

Description	Pages
Declaration of Dan DeNeui	App. 1–3
Declaration of Andrew Grossman	App. 4
Declaration of Lee Rosebush	App. 5–16
Exhibit 1	App. 17–49
Exhibit 2	App. 50–62
Exhibit 3	App. 63–65
Exhibit 4	App. 66–68
Exhibit 5	App. 69–72
Exhibit 6	App. 73–96
Exhibit 7	App. 97–101
Exhibit 8	App. 102–104
Exhibit 9	App. 105–111
Exhibit 10	App. 112–117
Exhibit 11	App. 118–122
Exhibit 12	App. 123–124
Exhibit 13	App. 125–130
Exhibit 14	App. 131–135
Exhibit 15	App. 136–172
Exhibit 16	App. 173–177
Exhibit 17	App. 178–180

Exhibit 18	App. 181–182
Exhibit 19	App. 183–186
Exhibit 20	App. 187–188
Exhibit 21	App. 189–190
Exhibit 22	App. 191–192
Exhibit 23	App. 193–194
Exhibit 24	App. 195–196
Exhibit 25	App. 197–198
Exhibit 26	App. 199–200
Exhibit 27	App. 201–202
Exhibit 28	App. 203–204
Exhibit 29	App. 205–206
Exhibit 30	App. 207–208
Exhibit 31	App. 209–210
Exhibit 32	App. 211–212
Exhibit 33	App. 213–215
Exhibit 34	App. 216–218
Exhibit 35	App. 219–223
Exhibit 36	App. 224–228
Exhibit 37	App. 229–234
Exhibit 38	App. 235–243
Exhibit 39	App. 244–311
Exhibit 40	App. 312–316

Certificate of Service

I hereby certify that a true and accurate copy of the foregoing document was filed electronically (via CM/ECF) on January 28, 2025, and that I caused a copy of the foregoing, and all accompanying papers, to be served via process server and via U.S. mail on the following:

United States Food and Drug Administration 10903 New Hampshire Ave. Silver Spring, Maryland 20903 Dated: January 28, 2025

/s/ Ty Doyle

TY DOYLE (Texas Bar No. 24072075)
BAKER & HOSTETLER LLP
811 Main Street, Suite 1100
Houston, TX 77002
(713) 646-1374
tgdoyle@bakerlaw.com

Attorney for Plaintiffs

Exhibit 15

From: no-reply@regulations.gov

To: Janacek, Benjamin

Subject: Your Comment Submitted on Regulations.gov (ID: FDA-2015-N-0030-0001)

Date: Tuesday, December 17, 2024 1:32:15 PM

[External Email: Use caution when clicking on links or opening attachments.]

Please do not reply to this message. This email is from a notification only address that cannot accept incoming email.

Your comment was submitted successfully! Comment Tracking Number: m4s-sjbk-e226

Your comment has been sent for review. This process is dependent on agency public submission policies/procedures and processing times. Once the agency has posted your comment, you may view it on <u>Regulations.gov</u> using your Comment Tracking Number.

Agency: FOOD AND DRUG ADMINISTRATION (FDA)

Document Type: Notice

Title: Compounding of Human Drug Products Under the Federal Food, Drug, and Cosmetic

Act; Establishment of a Public Docket Document ID: FDA-2015-N-0030-0001


Comment:


On behalf of the Outsourcing Facility Association, attached please find information demonstrating that FDA-approved GLP-1s are in shortage.

Uploaded File(s):

- 12.14 Hims and Hers_GLP1 Shortage_thru 12-14-24.pdf
- 12.14 Wholesaler data Vol 1.pdf
- 12.14 Wholesaler Data Vol 3.pdf
- 12.14 wholesalerdata Vol 2.pdf
- 12.16 Newer Diabetes Drugs Still Under.pdf
- 12.16 Petition Protect Patients Demand the FDA Ensure Access to Affordable GLP-1 Medications.pdf

For further information about the <u>Regulations.gov</u> commenting process, please visit <u>https://www.regulations.gov/faq</u>.








Home


Forms


My Account

Contact Us



Home > Search: mouni







Terms of Use | Privacy I

Copyright © 2010-2023 Capital Wholesale Drug Company - All Rights Reserved

Filed 01/28/25






Home

Forms


rms


My Account

Contact Us



Home > Search: zepbound







Terms of Use | Privacy I

Copyright © 2010-2023 Capital Wholesale Drug Company - All Rights Reserved

 $2.5 \text{ mg/0.5 mL (1)} \\ \text{Case 4:24-cv-0M9UNPARO 10 MG-PFP74X0.5 PM-d 01/28/25}$ 5 mg/0.5 mL (1) (/smtstorefront/bgb2b/en/AII-Rx-... PRE-FILLED PEN • 10 mg/0.5 mL • EA zc View More **Form** NDC #: 00002-1471-80 Product #: 10268696 PRE-FILLED PEN (6) LILLY ELI & CO Per Dose: \$534.5400 **Product Type** AWP: \$1,282.90 RX (6) ACQ Cost: \$1,069.08 Branded Vs. Generic 87 Branded (6) Available **Unit Dose** Add to Cart Non Unit Dose (6) Find Alternatives **Unit Size** Requires Refrigeration/Freezing Material Note 4x0.5 (6) Fine Line Category **MOUNJARO 5 MG PFP 4X0.5 ML** (/smtstorefront/bgb2b/en/AII-Rx-... All Rx Products (6) PRE-FILLED PEN • 5 mg/0.5 mL • EA zc **Generic Names** NDC #: 00002-1495-80 tirzepatide SUBCUT PEN Product #: 10268736 INJCTR 10MG/0.5ML (1) LILLY ELI & CO Per Dose: \$534.5400 tirzepatide SUBCUT PEN AWP: \$1,282.90 INJCTR 12.5MG/0.5 (1) tirzepatide SUBCUT PEN ACQ Cost: \$1,069.08 INJCTR 15MG/0.5ML (1) 41 Available tirzepatide SUBCUT PEN INJCTR 2.5 MG/0.5 (1) Add to Cart tirzepatide SUBCUT PEN **Find Alternatives**

Page 13 of 86 PageID 676

Your Offers

Generic Total \$0.00

Save 2% on brands when you spend \$250 in generics in one order. Code 2BRAND250DEC24

Click to **Apply**

Not

Applicable

"Expires December 31, 2024 at 11:59 pm ET. Qualifying amount of \$250 applies to Smart... View More

Instant Rebate - Save 2% on formulary generic items

Automatically applied - no code needed


Qualifying amount of \$100 applies to regularly priced SmartSource generics items and ... View More

View More

Manufacturer

INJCTR 5 MG/0.5ML (1)

Requires Refrigeration/Freezing



Requires Refrigeration/Freezing

Case 4:24-cv-M9UNPARQ 12.5 MG PFP14X0-5 ML-01/28/25 (/smtstorefront/bgb2b/en/All-Rx-... PRE-FILLED PEN • 12.5 mg/0.5 mL • EA zc NDC #: 00002-1460-80 Product #: 10268755 LILLY ELI & CO Per Dose: \$534.5400 AWP: \$1,282.90 ACQ Cost: \$1,069.08 44 Available - 1 + Add to Cart Find Alternatives

Requires Refrigeration/Freezing

Material Note

Account	Resources	Help	Legal				
Management My Orders (/smtstorefront/bgb2b/en/orders		Mobile App n/ ésnatatatætrot/b/gg/b/b/e/n/iw eb ile app)	Terms & Conditions n <u>(/ഓotktorefrodt/</u> 8 e bଥb/ቃ <u>n</u> ጸሎ iir)s and-conditions)				
orders)	Act (DSCSA)	Contact Sales / Repstexentarii/l egb2b/en/dscsa_re	Privacy Policy e ś/suntxte) efront/bgb2b/en/privac				
Support Services (/smtstorefront/bgb2b/en/self- service)	2024 Holiday Schedule Details	FAQs (/smtstorefront/bgb2b/en/faqs)	statement)				
My Invoices (/smtstorefront/bgb2b/en/invoice invoices)	(https://www.amerisourceberger schedules? es.my_source=Smt&utm_medium	n.com/holiday- Contact Us (/smtstorefront/bgb2b/en/contac Notice&utm_campaign=Holiday)	t -				
Receiving (/smtstorefront/bgb2b/en/receiv	FDA Drug Snortage	Llala Cantor					
Settings & Preferences (/smtstorefront/bgb2b/en/setting preferences)	shortages)	·					

Page 15 of 86 PageID 678

Case 4:24-cv-00953-P

Biosimilar Information Hub

Document 67(https://oiled.shartsourcerx.com/shitsbirdfresh/bgb28/46/bbs/millar-

hub)

Common Account Updates

Guide

(https://order.smartsourcerx.com/medias/sys_master/root/hed/hf0/h00/h00/14554230292510/24-

HGS-00201-Accountmaintenance-guide-14JUNE24-0V4.pdf)

340B Resources

(https://order.smartsourcerx.com/smtstorefront/bgb2b/en/smt340binformationhub)

Risk Evaluation and Mitigation Strategies

(https://order.smartsourcerx.com/smtstorefront/bgb2b/en/smt-

rems)

Copyright ©2024 AmerisourceBergen Corporation. All Rights Reserved.

Material Note

Requires Refrigeration/Freezing

App. 149

 $2.5 \text{ mg/0.5 mL (1)} \\ \text{Case 4:24-cv-} \text{\mathbb{Z}EBQUND-5.MG-BFP-4x0.5 MHed 01/28/25}$ 5 mg/0.5 mL (1) (/smtstorefront/bgb2b/en/AII-Rx-... PRE-FILLED PEN • 5 mg/0.5 mL • EA zc View More **Form** NDC #: 00002-2495-80 Product #: 10284369 PRE-FILLED PEN (6) LILLY ELI & CO Per Dose: \$529.9350 **Product Type** AWP: \$1,271.84 RX (6) ACQ Cost: \$1,059.87 Branded Vs. Generic 17 Branded (6) Available **Unit Dose** Add to Cart Non Unit Dose (6) Find Alternatives **Unit Size** Requires Refrigeration/Freezing 4x0.5 (6) ZEPBOUND 15 MG PFP 4X0.5 ML Fine Line Category (/smtstorefront/bgb2b/en/AII-Rx-... All Rx Products (6) PRE-FILLED PEN • 15 mg/0.5 mL • EA zc **Generic Names** NDC #: 00002-2457-80 tirzepatide SUBCUT PEN Product #: 10284412 INJCTR 10MG/0.5ML (1) LILLY ELI & CO Per Dose: \$529.9350 tirzepatide SUBCUT PEN AWP: \$1,271.84 INJCTR 12.5MG/0.5 (1) ACQ Cost: \$1,059.87 tirzepatide SUBCUT PEN INJCTR 15MG/0.5ML (1) Restricted tirzepatide SUBCUT PEN INJCTR 2.5 MG/0.5 (1) Add to Cart

Page 18 of 86 PageID 681

Your Offers

Generic Total \$0.00

Save 2% on brands when you spend \$250 in generics in one order. Code 2BRAND250DEC24

Click to **Apply**

Not

Applicable

"Expires December 31, 2024 at 11:59 pm ET. Qualifying amount of \$250 applies to Smart... View More

Instant Rebate - Save 2% on formulary generic items Automatically applied - no code needed

Qualifying amount of \$100 applies to regularly priced SmartSource generics items and ... View More

Find Alternatives

Requires Refrigeration/Freezing


Material Note

View More

Manufacturer

tirzepatide SUBCUT PEN

INJCTR 5 MG/0.5ML (1)



Requires Refrigeration/Freezing

Case 4:24-cv-ozepsound 25 MonRep 4X0.5 Med 01/28/25 (/smtstorefront/bgb2b/en/AII-Rx-... PRE-FILLED PEN • 2.5 mg/0.5 mL • EA zc NDC #: 00002-2506-80 Product #: 10284470 LILLY ELI & CO Per Dose: \$529.9350 AWP: \$1,271.84 ACQ Cost: \$1,059.87 25 Available - 1 + Add to Cart

Find Alternatives

Requires Refrigeration/Freezing

Account Resources Help Legal Management **Diversion Control & Security** Mobile App Terms & Conditions (https://order.smartsourcerx.com/s/smtststceft/ort/b/gb@b/e/Dimebsien(/sotsttotefrodt/Sgb@b/e/n\$Mtilis My Orders and-conditions) app) (/smtstorefront/bgb2b/en/orders/nDrug Supply Chain Security Act (DSCSA) **Contact Sales Privacy Policy** orders) (https://order.smartsourcerx.com/Preptstexefitarbit/legb2b/en/dscsa res/sumtets)refront/bgb2b/en/privac Support Services statement) 2024 Holiday Schedule **FAQs** (/smtstorefront/bgb2b/en/self-Details (/smtstorefront/bgb2b/en/faqs) service) (https://www.amerisourcebergen.com/holiday-Contact Us My Invoices schedules? (/smtstorefront/bgb2b/en/invoice es/mis-source=Smt&utm_medium=(/smtstorefront/bgb2b/en/contact-utm_source=Smt&utm_medium=(\subseteq \text{Qtice&utm_campaign=Holiday)} invoices) FDA Drug Shortage (https://www.fda.gov/drugs/drug-Help Center Receiving (/smtstorefront/bgb2b/en/receiving/aregy-arid-availability/drug-Request Price Stickers Settings & Preferences shortages) (/smtstorefront/bgb2b/en/settingsSafety Data Sheet (preferences) https://safetydata.cencora.com/)

Page 20 of 86

PageID 683

Case 4:24-cv-00953-P

Biosimilar Information Hub

Document 67(https://oiled.shartsourcerx.com/shristorefresh/bgb28/46/bbsshrifar-

hub)

Common Account Updates

Guide

(https://order.smartsourcerx.com/medias/sys_master/root/hed/hf0/h00/h00/14554230292510/24-

HGS-00201-Accountmaintenance-guide-14JUNE24-0V4.pdf)

340B Resources

(https://order.smartsourcerx.com/smtstorefront/bgb2b/en/smt340binformationhub)

Risk Evaluation and Mitigation Strategies

(https://order.smartsourcerx.com/smtstorefront/bgb2b/en/smt-

rems)

Copyright ©2024 AmerisourceBergen Corporation. All Rights Reserved.



▲ No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



Anda

MOUNJARO 12.5MG/0.5ML

NDC: 00002146080

Item: 805294 MFR: ELI LILLY 4 \$1,125.35

2

×

▲ Refrigerated Item: Ships Monday

▲ No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



MOUNJARO 7.5MG/0.5ML

NDC: 00002148480 Item: 805292

MFR: ELI LILLY

\$1,125.35

2

×

▲ Refrigerated Item: Ships Monday

▲ No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



MOUNJARO 10MG/0.5ML

NDC: 00002147180

Item: 805293 MFR: ELI LILLY 4 \$1,125.35

2

▲ Refrigerated Item: Ships Monday

A No Credit/No Return Refrigerated Item

▲ Daily Order Limit: 2

×

Standard

A No cressor to recommender seed rem

A Daily Order Limit: 2



Anda

MOUNJARO 12.5MG/0.5ML

NDC: 00002146080 Item: 805294

MFR: ELI LILLY

\$1,125.35

2

×

▲ Refrigerated Item: Ships Monday

▲ No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



MOUNJARO 7.5MG/0.5ML

NDC: 00002148480

Item: 805292 MFR: ELI LILLY \$1,125.35

2

×

A Refrigerated Item: Ships Monday

▲ No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



MOUNJARO 10MG/0.5ML

NDC: 00002147180

Item: 805293 MFR: ELI LILLY 4 \$1,125.35

▲ Refrigerated Item: Ships Monday

A No Credit/No Return Refrigerated Item

▲ Daily Order Limit: 2

×

SIZE \$



P.O. # Add PO# 6 items | \$13,504.20 Items

Anda

MOUNJARO 2.5MG/0.5ML

NDC: 00002150680

Item: 805290 MFR: ELI LILLY

ITEM DESCRIPTION \$

INJECTABLE PRE FILLED PEN NET B * 20

\$1,125.35

INV PRICE \$

QTY

PER UNIT

Q

×

A Refrigerated Item: Ships Monday

A No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



MOUNJARO 10MG/0.5ML

NDC: 00002147180

Item: 805293 MFR: ELI LILLY **INJECTABLE** PRE FILLED PEN NET B * 🗷 🖄

\$1,125.35

2

A Refrigerated Item: Ships Monday

A No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



MOUNJARO 12.5MG/0.5ML

NDC: 00002146080

Item: 805294 MFR: ELI LILLY INJECTABLE PRE FILLED PEN NET B * 🗖 🕢

\$1,125.35

2

×

A Refrigerated Item: Ships Monday

A No Credit/No Return Refrigerated Item


A Daily Order Limit: 2

App. 156

App. 157




Standard




Anda 🔾

Standard



NET B * 🗷 🖄



▲ No Credit/No Return Refrigerated Item

MFR: ELI LILLY

▲ Daily Order Limit: 2

App. 158

X

Q

×



Standard

A Refrigerated Item: Ships Monday

A No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



ZEPBOUND 2.5MG/0.5ML

NDC: 00002250680

Item: 805514 MFR: ELI LILLY

INJECTABLE PREFILLED PEN NET B * 🗖 🕢

\$1,115.65

2

X

A Refrigerated Item: Ships Monday

A No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



ZEPBOUND 12.5MG/0.5ML

NDC: 00002246080

Item: 805518 MFR: ELI LILLY INJECTABLE PREFILLED PEN NET B * 🗷 🖄

\$1,115.65

2

A Refrigerated Item: Ships Monday

A No Credit/No Return Refrigerated Item

A Daily Order Limit: 2



ZEPBOUND 7.5MG/0.5ML

NDC: 00002248480

Item: 805516 MFR: ELI LILLY **INJECTABLE** PREFILLED PEN NET B * 🗷 🖄

\$1,115.65

A Refrigerated Item: Ships Monday

▲ No Credit/No Return Refrigerated Item

A Daily Order Limit: 2

X

2

Case 4:24-cv-00953-P Document 67-1 Filed 01/28/25 Page 28 of 86 PageID 691 MOUNJARO 10MG/0.5ML SOLN

4X0.5ML

Item#: 214718

NDC: 00002-1471-80

Manufacturer: ELI LILLY AND COMPANY

Available: 7.00

Your Price:

\$1,175.99 Each

Add to Cart

+ Supply List



MOUNJARO 12.5MG/0.5ML SOL

4X0.5ML

Item#: 214608

NDC: 00002-1460-80

Manufacturer: ELI LILLY AND COMPANY

Available: 6.00

Your Price:

\$1,175.99 Each



Add to Cart

+ Supply List



MOUNJARO 15MG/0.5ML SOLN

4X0.5ML

Item#: 214578

NDC: 00002-1457-80

Manufacturer: ELI LILLY AND COMPANY

Available: 28.00

Your Price:

\$1,175.99 Each



Add to Cart

+ Supply List



MOUNJARO 2.5MG/0.5ML SOLN

4X0.5ML

Item#: 215068

NDC: 00002-1506-80

Manufacturer: ELI LILLY AND COMPANY

Available: 8.00

Your Price:

\$1,175.99 Each

Add to Cart

+ Supply List

App. 160



NDC: 00002-1506-80

Search Products...

	- musershie shoo cominni	No.		
	Home Forms My Account Contact Us			
Items in your ca	art			
Make any changes be	elow? Update			
No Photo	MOUNJARO 10MG/0.5ML SOLN 4X0.5ML Item #: 214718 NDC: 00002-1471-80	7 Avail:7.00	\$8,231.93 (\$1,175.99 EA)	
No Photo	MOUNJARO 12.5MG/0.5ML SOL 4X0.5ML Item #: 214608 NDC: 00002-1460-80	6 Avail:6.00	\$7,055.94 (\$1,175.99 EA)	
No Photo	MOUNJARO 15MG/0.5ML SOLN 4X0.5ML Item #: 214578 NDC: 00002-1457-80	28 Avail:28.00	\$32,927.72 (\$1,175.99 EA)	
8	MOUNJARO 2.5MG/0.5ML SOLN 4X0.5ML Item #: 215068	8 Avail:8.00	\$9,407.92 (\$1,175.99 EA)	




Search Products...


My Account Home **Forms** Contact Us 0 MOUNJARO 12.5MG/0.5ML SOL 4X0.5ML \$7,055.94 6 Item #: 214608 (\$1,175.99 EA) Avail:6.00 No Photo NDC: 00002-1460-80 0 MOUNJARO 15MG/0.5ML SOLN 4X0.5ML \$32,927.72 28 Item #: 214578 (\$1,175.99 EA) Avail:28.00 No Photo NDC: 00002-1457-80 0 MOUNJARO 2.5MG/0.5ML SOLN 4X0.5ML \$9,407.92 8 Item #: 215068 (\$1,175.99 EA) Avail:8.00 No Phote NDC: 00002-1506-80 0 MOUNJARO 5MG/0.5ML SOLN I 4X0.5ML \$57,623.51 49 Item #: 214958 (\$1,175.99 EA) Avail:49.00 No Photo NDC: 00002-1495-80 0



Item #: 214848

NDC: 00002-1484-80





PRODUCT DETAILS

NET Net Price Item 📵 Brand 🌞 Refrigerated 💆 Anda Contract 🙋 No Credit/No Return Refrigerated Item

Country of Origin: United States AWP Price: \$ 1,282.90

Savings ▼

Billing *

Search by number, name or keyword

55h 44m LEFT FOR DELIVERY ON MONDAY

PROMOS


Lists ▼

Orders ▼


\$20,198.10

Support *

Rebates: GRx 4% BRx 4% * Web 1% ~ Standard







eGate Portal

Case 4.24-cv-00953-P Document 67-1 Filed 01/28/25 Page 34 of 86 HQMED 697 LOOKUP ORDERS REPORTS RESOURCES CONTACT US LOG OUT

Search all Pr	oducts		Searc	h	Sale Items New Items	Search	By Category		All Contra	cts 🗸	Zero O	n Hand 🗾	Search	ı All				
Usa	Daily ge Max	Item	NDC/UPC	TE	Description ♦	Size ‡	Unit Cost≑	Cost≑	Avail≑	Note	Contract 	Sched Class	Gen Name	MFG	AWP	AWP Spread ‡	Retail	Details
	5	956698	00002148480	NR	REFRIGERATED	4X.5 ML SOA	534.54	\$1,069.08	100+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,282.92	16.67%	\$0.00	
•	5	987156	00002247180	NR	ZEPBOUND INJ 10MG/.5ML REFRIGERATED	4X.5 ML SOA	529.935	\$1,059.87	75+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,271.84	16.67%	\$0.00	
•	5	987164	00002246080	NR	ZEPBOUND INJ 12,5MG/.5ML REFRIGERATED	4X.5 ML SOA	529.935	\$1,059.87	25+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,271.84	16.67%	\$0.00	
•	5	987172	00002245780	NR	ZEPBOUND INJ 15MG/.5ML REFRIGERATED	4X.5 ML SOA	529.935	\$1,059.87	25+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,271.84	16.67%	\$0.00	
•	5	987123	00002250680	NR	ZEPBOUND INJ 2.5MG/.5ML REFRIGERATED	4X.5 ML SOA	529.935	\$1,059.87	25+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,271.84	16.67%	\$0.00	
•	5	987131	00002249580	NR	ZEPBOUND INJ 5MG/.5ML REFRIGERATED	4X.5 ML SOA	529.935	\$1,059.87	75+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,271.84	16.67%	\$0.00	
•	5	987149	00002248480	NR	ZEPBOUND INJ 7.5MG/.5ML REFRIGERATED	4X.5 ML SOA	529.935	\$1,059.87	50+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,271.84	16.67%	\$0.00 A n	(2) op. 166


eGate Portal Case 4:24-cv-00953-P Document 67-1 Filed 01/28/25 Page 35 of 86HOMED 698 LOOKUP ORDERS LOG OUT REPORTS RESOURCES CONTACT US Search all Products . . . Sale Items Search New Items Search By Category All Contracts Zero On Hand Search All


ПŲ	Usage	Daily Max	Item	NDC/UPC	TE	Description ≑	Size ≑	Unit Cost≑	Cost≑	Avail≑	Note	Contract 	Sched Class	Gen Name	MFG	AWP	AWP Spread ≎	Retail	Details
		5	956706	00002147180	NR	MOUNJARO 10MG/,5ML PREF PEN REFRIGERATED	4X.5 ML SOA	534.54	\$1,069.08	100+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,282.92	16.67%	\$0.00	
•		5	956714	00002146080	NR	MOUNJARO 12.5MG/.5ML PREF PEN REFRIGERATED	4X.5 ML SOA	534.54	\$1,069.08	100+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,282.92	16.67%	\$0.00	8
•		5	956722	00002145780	NR	MOUNJARO 15MG/.5ML PREF PEN REFRIGERATED	4X.5 ML SOA	534.54	\$1,069.08	100+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,282.92	16.67%	\$0.00	
•		5	956672	00002150680	NR	MOUNJARO 2.5MG/.5ML PREF PEN REFRIGERATED	4X.5 ML SOA	534.54	\$1,069.08	50+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,282.92	16.67%	\$0.00	
•		5	956680	00002149580	NR	MOUNJARO 5MG/.5ML PREF PEN REFRIGERATED	4X.5 ML SOA	534.54	\$1,069.08	100+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,282.92	16.67%	\$0.00	
•		5	956698	00002148480	NR	MOUNJARO 7,5MG/.5ML PREF PEN REFRIGERATED	4X.5 ML SOA	534.54	\$1,069.08	100+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,282.92	16.67%	\$0.00	(2)
•		5	987156	00002247180	NR	ZEPBOUND INJ 10MG/.5ML REFRIGERATED	4X.5 ML SOA	529.935	\$1,059.87	75+	* c		B-RX	TIRZEPAT	LILLY AN	\$1,271.84	16.67%	\$0.00	

NOTE: The information set forth in the tables is provided for internal use only, and is considered confidential. Availability (Avail) and Costs (Cost) are subject to change throughout the day which may affect the values appearing in the "AWP Spread" column.

Best Priced

App. 167






Search b	y number, name or keyword			COh Oom LEFT FOR MEXT DAY DELIVERY	PROMOS \$121.55
	ITEM DESCRIPTION:			INV PRICE \$ EST. NET PRIC	The maximum quantity available
	ZEPBOUND 10MG/0.5ML NDC: 00002247180 Item: 805517 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET (B) ** (2)		\$1,115.65 \$1,115.65	that you can order is 2 ADD Refrigerated tem: Ship Monday
	ZEPBOUND 15MG/0.5ML NDC: 00002245780 Item: 805519 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET(D) # 2 2		\$1,115.65 \$1,115.65	1 ADD Refrigerated Item: Ship Monday
	ZEPBOUND 5MG/0.5ML NDC: 00002249580 Item: 805515 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET (5)		\$1,115.65 \$1,115.65	1 ADD Refrigerated Item: Ship Monday
	ZEPBOUND 2.5MG/0.5ML NDC: 00002250680 Item: 805514 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET (B) ** (20)		\$1,115.65 \$1,115.65	1 ADD Refrigerated Item: Ships Monday
	ZEPBOUND 12.5MG/0.5ML NDC: 00002246080 Item: 805518 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET (E) # (20)		\$1,115.65 \$1,115.65	1 ADD Refrigerated Item: Ships Monday
	EEST PRICE ZEPBOUND 7.5MG/0.5ML NDC: 00002248480 Item: 805516	INJECTABLE PREFILLED PEN NET (B) *** (20)	4	\$1,115.65 \$1,115.65	1 ADD Refrigerated Item: Ships Monday

NET B * 20

MFR: ELI LILLY



Shopping Cart Summary

Item(s) will be added to your order.
You may modify the item or keep the current selection.

DEL CIN ITEM DESCRIPTION QTY COST

Cancel

5884911 ZEPBOUND SY 2,5MG/0,5ML 4 PPN [16] \$16,533.92

Exceeds Quantity Limit.

SUBTOTAL: \$16,533.92

12.5MG/0.5ML

15MG/0.5ML

e | Privacy Policy | Terms of Service | Feedback

5MG/O.5ML

7.5MG/0.5ML

10MG/0.5ML

und

UND

MUND

pagel 20 W

© 2024 Cardinal Health. All rights reserved.


Close

Add to Cart

Search by number, name or keyword

Case 4:24-cv-00953-P Document 67-1 Filed 01/28/25 Page 39 of 86 PageID 702

Your Cart (6 items) Empty Cart DELETE SELECTED P.O. # Add PO# 6 items | \$6,693.90 Items ITEM DESCRIPTION \$ SIZE \$ INV PRICE \$ PER UNIT QTY ✓ ZEPBOUND 10MG/0.5ML NDC: 00002247180 INJECTABLE 4 \$1,115.65 — PREFILLED PEN Item: 805517 NET 🗈 🤻 💆 🕢 MFR: ELI LILLY A Refrigerated Item: Ships Monday ▲ No Credit/No Return Refrigerated Item ▲ Daily Order Limit: 2 ZEPBOUND 5MG/0.5ML INJECTABLE NDC: 00002249580 4 \$1,115.65 — 1 PREFILLED PEN Item: 805515 NET 🛛 🕸 💆 🕢 MFR: ELI LILLY A Refrigerated Item: Ships Monday A No Credit/No Return Refrigerated Item ▲ Daily Order Limit: 2 ▽ ZEPBOUND 2.5MG/0.5ML NDC: 00002250680 INJECTABLE 1 4 \$1,115.65 — PREFILLED PEN Item: 805514 NET 🗈 🤻 🗖 🕢 MFR: ELI LILLY A Refrigerated Item: Ships Monday A No Credit/No Return Refrigerated Item ▲ Daily Order Limit: 2 NDC: 00002245780 INJECTABLE 4 \$1,115.65 — PREFILLED PEN Item: 805519 NET B 🕸 💆 🥝 MFR: ELI LILLY A Refrigerated Item: Ships Monday A No Credit/No Return Refrigerated Item ▲ Daily Order Limit: 2 ZEPBOUND 12.5MG/0.5ML NDC: 00002246080 INJECTABLE 1 4 \$1,115.65 — PREFILLED PEN Item: 805518 NET 🛭 🕸 🗖 🔕 MFR: ELI LILLY A Refrigerated Item: Ships Monday A No Credit/No Return Refrigerated Item ▲ Daily Order Limit: 2 NDC: 00002248480 INJECTABLE 4 \$1,115.65 — Item: 805516 PREFILLED PEN NET 🛭 🔻 💆 🔕 MFR: ELI LILLY A Refrigerated Item: Ships Monday ▲ No Credit/No Return Refrigerated Item ▲ Daily Order Limit: 2



\$6,693.90


Search by number, name or keyword


Q 55

55h 57m LEFT FOR DELIVERY ON MONDAY

PROMOS







Meeting Coverage > ASHP

Newer Diabetes Drugs Still Under-Prescribed in High-Risk Patients

— Cost, insurance coverage likely play outsized role

by Sophie Putka, Enterprise & Investigative Writer, MedPage Today December 16, 2024











NEW ORLEANS -- Patients at a community health center who had type 2 diabetes and a high risk of atherosclerotic cardiovascular disease (ASCVD) were under-prescribed guideline-recommended treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists, a single-center study found.

Of patients who met the high-risk criteria, 55% were not on American Diabetes Association (ADA) guidelinedirected medication therapy with an SGLT-2 inhibitor or GLP-1 agonist. In only 34% of these cases was there an appropriate documented reason given, said Holly C. Johnson, PharmD, of Atrium Health Navicent in Macon, Georgia, who presented the findings at the American Society of Health-System Pharmacists midyear meeting here.

The ADA has recommended use of SGLT-2 inhibitors as first-line drugs for patients with diabetes and cardiovascular disease since 2019, after several trials demonstrated substantial benefit for SGLT-2 inhibitors in these patients. Other major societies have also updated

Case 4:24-cv-00953-P Document 67-1 recommend use of SGLT-2 inhibitors for PageID 706 these patients. Johnson added that GLP-1 agonists can also be used as they've shown heart benefits as well.

However, uptake of these medications has been slow, and according to previous studies, sulfonylureas and dipeptidyl peptidase-4 inhibitors continue to be more commonly prescribed. SGLT-2 inhibitors include empagliflozin (Jardiance) and dapagliflozin (Farxiga), and GLP-1 agonists include semaglutide (Ozempic) and liraglutide (Victoza).

Johnson said WT Anderson Community Health Center Resident Medicine Clinic in Macon, where the study was conducted, treats a "very underserved," and "very poorly insured" population who were mostly taking metformin to control diabetes. The clinic offers a patient assistance program for certain drugs; research has found that both SGLT2 inhibitors and GLP-1 agonists cost much more than metformin over a patient's lifetime. Poor uptake of these drugs is consistent with other research that has found disparities in the prescribing of these agents to adults with diabetes and cardiovascular disease by race, ethnicity, and income.

"The use of these evidence-based medications remains low. We need to work on both therapeutic inertia ... as well as other contextual barriers which are important (for example, financial barriers and lack of coverage)," Salim S. Virani, MD, PhD, of Aga Khan University in Karachi, Pakistan, who was not involved in the study but has researched utilization rates of SGLT-2 inhibitors, told *MedPage Today* in an email.

"Multipronged efforts need to be directed towards clinicians, patients, and the healthcare system to ensure that clinicians can prescribe the medications easily, that

Case 4:24-cv-00953-P Bocument 67-1 Filed 01/28/25 after discussing PageID 707 this with the patients, and that patients take the medications as prescribed," Virani added.

Medical News from Around the Web	

FORBES

This Startup Makes A Vaccine For Honeybees. Shrimp Are Next.

CLINICAL ADVISOR

Epidural Steroid Injections for Radicular Pain May Increase Fracture Risk

BECKER'S HOSPITAL REVIEW

Experts slam claims that vaccines overwhelm immune systems

Johnson and colleagues included patients age 18 or older seen at WT Anderson from January through March 2024. All had a diagnosis of type 2 diabetes and either a history of ASCVD or at least two additional risk factors such as end-organ damage, hypertension, smoking, or dyslipidemia.

Patients with a previously documented reason for not taking a GLP-1 agonist or SGLT-2 inhibitor were excluded, as were those visiting for a blood pressure check, nurse visit, or injection/vaccine. Only one visit from each patient was included in the study period.

In all, 180 patients were classified as high-risk. Of the 99 patients who were not on either a GLP-1 agonist or an SGLT-2 inhibitor, approximately one-third had a documented reason. For SGLT-2 inhibitors, the most common reasons given were having an A1C \geq 9% (42%), intolerance to the agent (19%), and financial constraints (16%). For GLP-1 agonists, the top reason given was financial constraints (55%), followed by patient preference and intolerance (18% each).

no documented or presumed reason for not having an SGLT-2 prescription had a controlled hemoglobin A1c < 7%. She said it is possible that the prescribing clinician may have not added the medication if the patient's condition was controlled. But, "you're still at high risk for stroke or heart failure, no matter what your A1c is," she stressed.

"For SGLT-2s, I did not realize I was going to find if they're controlled, they're not starting it. So now that's my thing," Johnson added. "I'm going to make sure there is more education out there. So if your A1c is controlled, you still need to be on one of these agents."

Study limitations included that the research was conducted at a single center and thus may not be generalizable to other healthcare facilities or populations, and that the researchers did not collect demographic information about the patients.

Sophie Putka is an enterprise and investigative writer for MedPage Today. Her work has appeared in the Wall Street Journal, Discover, Business Insider, Inverse, Cannabis Wire, and more. She joined MedPage Today in August of 2021. Follow

Disclosures

Johnson and co-authors reported no financial conflicts of interest. Virani reported financial relationships with the American College of Cardiology.

Primary Source

American Society of Health-System Pharmacists

Source Reference: Johnson HC, et al "Evaluation of guideline-directed medication therapy prescribing of GLP-1 agonists and SGLT2 inhibitors in type two diabetic patients with or at high-risk of atherosclerotic vascular disease" ASHP 2024; Abstract 10-006.

2 Comments

change.org





Protect Patients: Demand the FDA Ensure Access to Affordable GLP-1 Medications!

Sign Petition

14,281

Verified signatures 🗸

Moises Santiago • 33 minutes ago

Brandall Redd • 1 hour ago

Kelsey Otte • 1 hour ago

Lorai



Decision Makers: Food and Drug Administration +1



6 Updates



2 Media Mentions

The Issue

Millions of patients across the U.S. depend on GLP-1 medications like Tirzepatide (Mounjaro, Zepbound) and Semaglutide (Ozempic, Wegovy) to manage chronic conditions such as type 2 diabetes, obesity, and PCOS. These medications are life-saving for many, helping to prevent severe complications and significantly improving their quality of life. Unfortunately, ongoing shortages and the sky-high cost of brand-name drugs have left countless patients struggling to access the treatments they desperately need, often forcing them to turn to compounding pharmacies for relief.

What is at stake?

If the FDA fails to recognize the ongoing shortages and does not support affordable compounded alternatives, millions of patients will lose access to these critical medications. The potential shutdown of compounding pharmacies—due to regulatory restrictions and pressure from big pharmaceutical companies—will strip away one of the few affordable options available to patients. Without immediate change, people will face declining health, worsening conditions, and overwhelming financial burdens.

Why is now the time to act?

The FDA's recent decisions suggest a troubling prioritization of pharmaceutical profits over patient needs. Shortages are still limiting access, and the cost of brand-name medications remains out of reach for many. Now is the time to stand up for patients who rely on these life-saving drugs. Sign this petition to demand that the FDA prioritize patients by addressing ongoing shortages, supporting compounded alternatives, and ensuring that everyone has access to the treatments they need to live healthy, fulfilling lives.

Sign and share this petition today!

Report a policy violation



Amanda Bonello


Petition Starter

Media inquiries


335 people signed today

GLP-1 Shortage Responses by Drug (Week of 2024-10-20)

of patients, by week and drug, who indicated they could not access branded GLP-1s




Cumulative Weekly GLP-1 Shortage Responses by Drug (2024-09-01 onwards) # of patients, by week and drug, who indicated they could not access branded GLP-1s



Cumulative Shortage Responses by Drug (2024-09-01 onwards)

of patients by drug, who indicated they could not access branded GLP-1s



From: no-reply@regulations.gov

To: Janacek, Benjamin

Subject: Your Comment Submitted on Regulations.gov (ID: FDA-2015-N-0030-0001)

Date: Wednesday, December 18, 2024 4:39:18 PM

[External Email: Use caution when clicking on links or opening attachments.]

Please do not reply to this message. This email is from a notification only address that cannot accept incoming email.

Your comment was submitted successfully! Comment Tracking Number: m4u-enhu-fgt5

Your comment has been sent for review. This process is dependent on agency public submission policies/procedures and processing times. Once the agency has posted your comment, you may view it on <u>Regulations.gov</u> using your Comment Tracking Number.

Agency: FOOD AND DRUG ADMINISTRATION (FDA)

Document Type: Notice

Title: Compounding of Human Drug Products Under the Federal Food, Drug, and Cosmetic

Act; Establishment of a Public Docket Document ID: FDA-2015-N-0030-0001

Comment:

On behalf of the Outsourcing Facility Association, attached please find evidence that FDA-approved GLP-1s are in shortage.

Uploaded File(s):

12.17 Update Ozempic supply to remain limited in 2025 Therapeutic Goods Administration (TGA).pdf

12.18 Ozempic shortages roll on.pdf

12.18 Petition Protect Patients Demand the FDA Ensure Access to Affordable GLP-1 Medications.pdf

Mounjaro - Zepbound Stock 12.13.2024.pdf

Mounjaro Shortage 2 12.18.pdf

Mounjaro Shortage 3 12.18.pdf

Mounjaro Shortage 4 12.18.pdf

Mounjaro Shortage 12.18.pdf

WEGovy Shortage 2 12.18.pdf

WeGovy Shortage 12.18.pdf

Zep Mounjaro Shortage 2 12.18.pdf

Zep Mounjaro Shortage 3 12.18.pdf

Zep Mounjaro Shortage 4 12.18.pdf

Zep Mounjaro Shortage 5 12.18.pdf

Zep Mounjaro Shortage 6 12.18.pdf

Zep Mounjaro Shortage 7 12.18.pdf

Zep Mounjaro Shortage 12.18.pdf

Zep Shortage 2 12.18.pdf

Zep Shortage 3 12.18.pdf

Zep Shortage 4 12.18.pdf

For further information about the $\underline{Regulations.gov}$ commenting process, please visit $\underline{https://www.regulations.gov/faq}$.


Mounjaro		On-Hand	SV 101 Allocation		
	5787239	154		24	
	5787205	384		3	
	5787213	118		24	
	5787221	200		24	
	5787189	337		24	
	5787197	527		24	
Zepbound					
	5884911	54		24	
	5884929	68		24	
	5884937	106		3	
	5884945	57		24	
	5884952	44		24	
	5884960	89		3	





	Showing 1 - 12	of 12 results for "tirzepatide"	Document of 1	u 01/20/	25 1 age 50	0100 10	Igcid 121	VIEW: 25 50 100
*		ITEM DESCRIPTION \$		SIZE \$	INV PRICE \$ EST	T. NET PRIC	PER UNIT	QΤΥ
*	mountairo	MOUNJARO 15MG/0.5ML NDC: 00002145780 Item: 805295 MFR: ELI LILLY	INJECTABLE PRE FILLED PEN NET B * 2000	4	\$1,125.35 \$	51,125.35	-	2 ADD Refrigerated Item
*		MOUNJARO 5MG/0.5ML NDC: 00002149580 Item: 805291 MFR: ELI LILLY	INJECTABLE PRE FILLED PEN NET B * 2000	4	-	-	_	Notify me when this item is in stock
*	TOO PER CONTROL OF THE CONTROL OF TH	MOUNJARO 7.5MG/0.5ML NDC: 00002148480 Item: 805292 MFR: ELI LILLY	INJECTABLE PRE FILLED PEN NET B * 200	4	\$1,125.35 \$	51,125.35	_	2 ADD Refrigerated Item
>	MOZATORY MOZ	MOUNJARO 2.5MG/0.5ML NDC: 00002150680 Item: 805290 MFR: ELI LILLY	INJECTABLE PRE FILLED PEN NET B * 2000	4	\$1,125.35 \$	51,125.35	-	2 ADD Refrigerated Item
>	months of the same	MOUNJARO 12.5MG/0.5ML NDC: 00002146080 Item: 805294 MFR: ELI LILLY	INJECTABLE PRE FILLED PEN NET B * 200	4	\$1,125.35 \$	51,125.35	-	2 ADD Refrigerated Item
	Pecarjaro procession de la companya	MOUNJARO 10MG/0.5ML NDC: 00002147180 Item: 805293 MFR: ELI LILLY	INJECTABLE PRE FILLED PEN NET B * 2000	4	\$1,125.35 \$	51,125.35	_	2 ADD Refrigerated Item


App. 190





















talog: Search Results

NE RESULTS • 1 currently applied filter(s)															
MCK ITEM #	HIST	DESCRIPTION	EST. NET PRICE	PURCHASE PRICE	UNIT PRICE	PRICE IND	DC QTY	ORD QTY	DO NOT SUB	GEN EQUIV	AVAIL QTY	FILL DC	VENDOR SUPPLY	RETAIL PRICE	UOM
2878411		ZEPBOUND 15MG/0.5MLX4PEND AM	\$1014.19	\$1014.19	\$507.0950		>100	•	0	GE	5		Detail	Edit	СТ
2617892		MOUNJARO12.5MG/0.5MLX4PEND AM	\$1023.00	\$1023.00	\$511.5000		>100	•	0	GE	5			Edit	СТ
2878353		ZEPBOUND 7.5MG/0.5MLX4PEND AM	\$1014.19	\$1014.19	\$507.0950		>100	\$		GE	5			Edit	СТ
2878361		ZEPBOUND 10MG/0.5MLX4PEND AM	\$1014.19	\$1014.19	\$507.0950		>100	•		GE	5			Edit	СТ
2617900		MOUNJARO15MG/0.5MLX4PEND AM	\$1023.00	\$1023.00	\$511.5000		>100	-		GE	5			Edit	СТ
2617868		MOUNJARO 5MG/0.5MLX4PEND AM	\$1023.00	\$1023.00	\$511.5000		>100	•	0	GE	5		Detail	Edit	СТ
2617884		MOUNJARO 10MG/0.5MLX4PEND AM	\$1023.00	\$1023.00	\$511.5000		>100	\$		GE	5		Detail	Edit	CT
2878338		ZEPBOUND 5MG/0.5MLX4PEND AM	\$1014.19	\$1014.19	\$507.0950		>100	•	0	GE	>100			Edit	СТ
2878320	HST	ZEPBOUND 2.5MG/0.5MLX4PEND AM	\$1014.19	\$1014.19	\$507.0950		>100	\$	0	GE	5			Edit	СТ
2878379		ZEPBOUND12.5MG/0.5MLX4PEND AM	\$1014.19	\$1014.19	\$507.0950		25	\$	0	GE	25			Edit	СТ
	MCK ITEM # 2878411 2617892 2878353 2878361 2617900 2617868 2617884 2878338 2878320	MCKITEM # HIST 2878411 2617892 2878353 2878361 2617900 2617868 2617884 2878338 2878320 HST	MCK ITEM # HIST DESCRIPTION 2878411 ZEPBOUND 15MG/0.5MLX4PEND AM 2617892 MOUNJARO12.5MG/0.5MLX4PEND AM 2878353 ZEPBOUND 7.5MG/0.5MLX4PEND AM 2878361 ZEPBOUND 10MG/0.5MLX4PEND AM 2617900 MOUNJARO15MG/0.5MLX4PEND AM 2617868 MOUNJARO 5MG/0.5MLX4PEND AM 2878338 ZEPBOUND 10MG/0.5MLX4PEND AM 2878320 HST 2878379 ZEPBOUND 2.5MG/0.5MLX4PEND	MCK ITEM # HIST DESCRIPTION EST. NET PRICE 2878411 ZEPBOUND 15MG/0.5MLX4PEND AM \$1014.19 2617892 MOUNJARO12.5MG/0.5MLX4PEND AM \$1023.00 2878353 ZEPBOUND 7.5MG/0.5MLX4PEND AM \$1014.19 2878361 ZEPBOUND 10MG/0.5MLX4PEND AM \$1014.19 2617900 MOUNJARO15MG/0.5MLX4PEND AM \$1023.00 2617868 MOUNJARO 5MG/0.5MLX4PEND AM \$1023.00 2617884 MOUNJARO 10MG/0.5MLX4PEND AM \$1023.00 2878338 ZEPBOUND 5MG/0.5MLX4PEND AM \$1014.19 2878379 ZEPBOUND 2.5MG/0.5MLX4PEND S1014.19 \$1014.19	MCK ITEM # HIST DESCRIPTION EST. NET PRICE PURCHASE PRICE 2878411 ZEPBOUND 15MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$1014.19 2617892 MOUNJARO12.5MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$1023.00 2878353 ZEPBOUND 7.5MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$1014.19 2878361 ZEPBOUND 10MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$1014.19 2617900 MOUNJARO15MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$1023.00 2617868 MOUNJARO 5MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$1023.00 2617884 MOUNJARO 10MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$1014.19 2878338 ZEPBOUND 5MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$1014.19 2878379 ZEPBOUND 2.5MG/0.5MLX4PEND \$1014.19 \$1014.19 \$1014.19	MCK TEM HIST DESCRIPTION EST. NET PURCHASE UNIT PRICE	MCKITEM	MCKITEM # HIST DESCRIPTION EST. NET PRICE PURCHASE PRICE UNIT PRICE PRICE IND DC QTY 2878411 ZEPBOUND 15MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$507.0950 >100 2617892 MOUNJARO12.5MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$511.5000 >100 2878353 ZEPBOUND 7.5MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$507.0950 >100 2878361 ZEPBOUND 10MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$507.0950 >100 2617900 MOUNJARO15MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$511.5000 >100 2617868 MOUNJARO 5MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$511.5000 >100 2878338 ZEPBOUND 5MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$507.0950 >100 2878320 IIST ZEPBOUND 2.5MG/0.5MLX4PEND AM \$1014.19 \$507.0950 >100 28783370 ZEPBOUND 2.5MG/0.5MLX4PEND \$1014.19 \$1014.19 \$507.0950 >100	MCK ITEM # HIST DESCRIPTION EST. NET PRICE PURCHASE PRICE UNIT PRICE PRICE IND DC QTY ORD QTY 2878411 ZEPBOUND 15MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$507.0950 >100 ♣ 2617892 MOUNJARO12.5MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$511.5000 >100 ♣ 2878353 ZEPBOUND 7.5MG/0.5MLX4PEND AM \$1014.19 \$507.0950 >100 ♣ 2878361 ZEPBOUND 10MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$507.0950 >100 ♣ 2617900 MOUNJARO15MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$511.5000 >100 ♣ 2617884 MOUNJARO 10MG/0.5MLX4PEND AM \$1023.00 \$1023.00 \$511.5000 >100 ♣ 2878338 ZEPBOUND 5MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$507.0950 >100 ♣ 2878330 ZEPBOUND 2.5MG/0.5MLX4PEND AM \$1014.19 \$1014.19 \$507.0950 >100 ♣ 28783370 ZEPBOUND 12.5MG/0.5MLX4PEND \$1014.19 \$101	MCKITEM	MCKITEM HIST DESCRIPTION EST. NET PRICE PRICE UNIT PRICE PRICE IND DC QTY ORD QTY SUB EQUIV	MCKITEM	MCK/TEM	NCK/TEM HIST DESCRIPTION FST. NET PURCHASE PRICE PRICE	NCKTIFM HIST DESCRIPTION FST NET PRICE PUNCT PRICE UNIT PRICE PRICE IND DC QTY ORD QTY SUB EQUIV QTY FILL DC SUPPLY PRICE SUPPLY PRICE PRICE UNIT PRICE PRICE IND DC QTY ORD QTY SUB EQUIV QTY FILL DC SUPPLY PRICE PRICE SUPPLY PRICE

ZEPBOUND 7.5MG/0.5ML NDC: 00002248480 Item: 805516 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET B * 2000	4	\$1,115.65 \$1,115.65	_	1 ADD Refrigerated Item
ZEPBOUND 5MG/0.5ML NDC: 00002249580 Item: 805515 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET * Ø	4	\$1,115.65 \$1,115.65	_	1 ADD Refrigerated Item
ZEPBOUND 10MG/0.5ML NDC: 00002247180 Item: 805517 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET B * 2000	4	\$1,115.65 \$1,115.65	_	1 ADD Refrigerated Item
ZEPBOUND 2.5MG/0.5ML NDC: 00002250680 Item: 805514 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET B * 2 00	4	\$1,115.65 \$1,115.65	_	1 ADD Refrigerated Item
ZEPBOUND 12.5MG/0.5ML NDC: 00002246080 Item: 805518 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET B * 2000	4	\$1,115.65 \$1,115.65	_	1 ADD Refrigerated Item
ZEPBOUND 15MG/0.5ML NDC: 00002245780 Item: 805519 MFR: ELI LILLY	INJECTABLE PREFILLED PEN NET B * 200	4		_	Notify me when this item is in stock



KEFINE	KESULIS *	r currently applied litter(s)											
IMAGE	MCK ITEM HIST A	DESCRIPTION	EST. NET PRICE	PURCHASE PRICE	UNIT PRICE 4 ³	PRICE IND	DC QTY	ORD QTY	DO NOT SUB	GEN EQUIV	AVAIL QTY	FILL DC	VENDOR SUPPLY
	2878338	ZEPBOUND 5MG/0.5MLX4PEND AM	\$1033.37	\$1033.37	\$516.6850		>100	\$		GE	>100		
	2878411	ZEPBOUND 15MG/0.5MLX4PEND AM	\$1033.37	\$1033.37	\$516.6850		>100	•	0	GE	5		Detail
	2878353	ZEPBOUND 7.5MG/0.5MLX4PEND AM	\$1033.37	\$1033.37	\$516.6850		>100	\$		GE	5		
	2878361	ZEPBOUND 10MG/0.5MLX4PEND AM	\$1033.37	\$1033.37	\$516.6850		>100	\$	0	GE	5		
	2878320	ZEPBOUND 2.5MG/0.5MLX4PEND AM	\$1033.37	\$1033.37	\$516.6850		>100	\$		GE	5		
	2878379	ZEPBOUND12.5MG/0.5MLX4PE AM	\$1033.37	\$1033.37	\$516.6850		>100	\$	0	GE	>100		



Submission time	First name	Last name	Email	Zip Code	Have you attempted to have a prescription filled at more than one pharmacy?
2024-10-16T15:04:45.625Z				14214	
2024-10-15T20:36:16.559Z				75645	
2024-10-15T20:33:41.002Z				75645	
2024-10-15T15:33:19.314Z				78108	
2024-10-15T13:30:46.683Z				08361	Yes
2024-10-15T13:30:36.407Z				08360	Yes
2024-10-15T12:39:18.018Z				33513	
2024-10-15T04:46:23.224Z				54487	
2024-10-15T01:51:46.448Z				34684	
2024-10-14T03:09:16.846Z				29577	
2024-10-13T17:42:24.526Z				80210	
2024-10-13T14:19:50.778Z 2024-10-12T18:21:03.127Z				00000	Yes
2024-10-12T 18:21:03.127Z 2024-10-12T05:22:46.877Z	-			44320 78724	
2024-10-12T03:22:40:8772 2024-10-12T01:15:53:661Z				36861	
2024-10-12101.13.33.0012 2024-10-11T17:39:40.759Z	-			38057	
2024-10-11117.39.40.739Z 2024-10-11T16:10:42.457Z				92663	
2024-10-11T16:04:47.783Z				04612	No
2024-10-11T14:38:56.533Z				76132	
2024-10-11T13:25:59.334Z	-			75482	
2024-10-11T03:51:37.099Z	-			89521	
2024-10-11T02:12:22.011Z				92058	
2024-10-11T02:12:22:011Z				97302	
2024-10-11102:11:39:3542 2024-10-10T23:21:14.865Z				78756	
2024-10-10T23:21:14:0032 2024-10-10T22:51:03.692Z				97229	
2024-10-10T22:50:47.678Z				32218	
2024-10-10T21:31:18.808Z				37922	
2024-10-10T20:08:30.024Z				46350	
2024-10-10T18:47:26.304Z				11222	
2024-10-10T17:16:59.871Z				49417	
2024-10-10T13:29:22.608Z				70065	
2024-10-10T12:53:30.592Z				63028	Yes
2024-10-10T04:21:50.777Z				34787	
2024-10-10T03:50:07.958Z				98223	Yes
2024-10-10T03:29:44.117Z				48042	Yes
2024-10-09T23:58:12.593Z				28451	Yes
2024-10-09T22:06:30.330Z				07828	Yes
2024-10-09T19:26:29.390Z				78737	Yes
2024-10-09T18:17:48.877Z				29316	Yes
2024-10-09T18:13:04.011Z				64116	Yes
2024-10-09T18:02:48.124Z				11412	
2024-10-09T18:01:00.866Z	-			55082	
2024-10-09T17:41:32.781Z				10034	
2024-10-09T16:02:23.446Z				45040	
2024-10-09T15:37:13.168Z				37203	
2024-10-09T15:36:41.283Z				33496	
2024-10-09T15:25:38.317Z				20850	
2024-10-09T15:25:10.560Z				20852	
2024-10-09T15:24:46.199Z				19148	
2024-10-09T15:22:11.025Z				33056	
2024-10-09T14:49:03.151Z 2024-10-09T14:22:54.693Z				20109	
2024-10-09T14:22:54.693Z 2024-10-09T13:27:24.822Z				60062 05679	
2024-10-09T13:27:24.822Z 2024-10-09T13:26:08.726Z				11373	Yes Vac
2024-10-09T13:26:08.726Z 2024-10-09T13:25:28.924Z				11373	
2024-10-09T13:24:43.183Z				11101	
2024-10-09T13:24:45:163Z				28227	
2024-10-09T12:43:02.331Z				77406	
2024-10-09T12:39:59.886Z				24073	
2024-10-03T12:03:03:0002 2024-10-09T12:29:09.024Z				49740-9313	
2024-10-09T12:02:14.247Z				43054	
2024-10-03T12:02:14:2472 2024-10-09T11:58:56.464Z				49770	
2024-10-09T11:31:40.819Z				60441	
2024-10-09T11:10:35.741Z				44203	
2024-10-09T11:07:39.347Z				75028	
2024-10-09T09:24:17.991Z				49770	Yes
2024-10-09T09:23:44.058Z				49770	Yes
2024-10-09T09:23:17.551Z				49770	Yes
2024-10-09T08:45:55.094Z				49770	Yes
2024-10-09T08:16:19.027Z				45840	
2024-10-09T08:16:18.556Z				18424	
2024-10-09T07:54:44.630Z				34655	Yes
2024-10-09T06:39:15.994Z				30019	
2024-10-09T06:30:46.790Z				60016	
2024-10-09T04:42:16.522Z				37203	
2024-10-09T04:33:41.180Z				33781	
2024-10-09T04:21:41.176Z				90034	
2024-10-09T04:09:59.473Z				42660	
2024-10-09T04:07:45.422Z				97601	Yes

2024-10-09T03:49:29.901Z	98272	2 Yes
2024-10-09T03:46:23.174Z	75020	0 Yes
2024-10-09T03:45:41.624Z	98684	4 No
2024-10-09T03:45:41.137Z	97060	0 Yes
2024-10-09T03:22:15.457Z	95118	8 Yes
2024-10-09T03:17:08.206Z	11692	2 Yes
2024-10-09T03:16:45.141Z	55105	5 Yes
2024-10-09T03:16:35.671Z	97123	3 Yes
2024-10-09T03:16:27.218Z	64081	1 Yes
2024-10-09T03:13:13.748Z	33186	6 Yes
2024-10-09T03:02:11.454Z	18407	7 Yes
2024-10-09T02:59:51.127Z	95224	4 Yes
2024-10-09T02:53:11.168Z	65806	6 Yes
2024-10-09T02:40:09.601Z	80226	6 Yes
2024-10-09T02:39:47.083Z	27560	0 Yes
2024-10-09T02:39:02.915Z	89506	6 Yes
2024-10-09T02:20:22.237Z	23323	3 Yes
2024-10-09T02:17:54.618Z	77584	4 Yes
2024-10-09T02:14:22.540Z	94706	6 Yes
2024-10-09T02:13:03.836Z	23323	3 Yes
2024-10-09T02:06:56.690Z	97322	2 Yes
2024-10-09T01:51:52.235Z	89014	4 No
2024-10-09T01:39:05.688Z	92311	1 Yes
2024-10-09T00:03:46.301Z	07010	Yes
2024-10-08T18:45:44.458Z	78723	3 Yes
2024-10-08T17:32:46.831Z	83616	6 Yes